Non‑Antibiotic Strategies Against Acinetobacter baumannii: Review Highlights

A narrative review in Antibiotics surveys emerging non-antibiotic and adjunctive approaches for controlling multidrug-resistant Acinetobacter baumannii, describing a literature base that is largely laboratory and model-system work, with fewer in vivo and human reports. The authors organize the discussion into four broad strategy domains: disrupting essential metabolic pathways, nanotechnology-based delivery and metal nanoparticles, bacteriophages, and repurposing approved drugs as alternative or adjunctive candidates. Across sections, the review points to common challenges these modalities aim to address, including limited antibiotic penetration, biofilm persistence, and rising resistance phenotypes.

In the metabolic-targeting section, the authors describe efforts to “hijack” A. baumannii’s metabolic adaptability by focusing on pathways and nodes discussed as relevant to fitness, resistance phenotypes, or virulence in experimental systems, including examples from carbon utilization and central metabolism. They also note studies that combine metabolic perturbations with conventional agents in animal infection models, presenting these as observations supporting further exploration rather than established clinical approaches. In parallel, the drug-repositioning section frames repurposing as leveraging existing development pathways and safety datasets, while noting that antimicrobial activity is most often shown in screening-style in vitro assays and selected in vivo models. Examples in the review include selective serotonin reuptake inhibitors (such as sertraline, paroxetine, and fluoxetine) and the calcium channel blocker fendiline, which the authors describe as having reported activity against A. baumannii in preclinical studies. The review also highlights translational constraints for repurposed agents, including an author-described gap between inhibitory concentrations reported in vitro and plasma levels typically achieved with standard dosing, leaving this category predominantly preclinical in the synthesis.

The section on bacteriophage therapy presents phages as a targeted biologic modality whose development pipeline, as reviewed, spans genomic characterization, host-range assessment, and testing in vitro and in animal models. The authors describe how contemporary phage selection often includes genome-based screening for features viewed as undesirable for therapeutic development, and how the narrow host range of many phages motivates cocktails or personalized matching approaches. In vivo findings summarized in the review include model-system reports of improved survival and reduced bacterial burden in settings such as pneumonia or sepsis models; the narrative also includes compassionate-use clinical case reports in which phages were administered alongside antibiotics, with clinical and microbiologic changes described over short time horizons. The authors also outline operational and biologic challenges for translation, including the lack of standardized host-range or phage susceptibility workflows comparable to antibiotic testing and the potential for immune clearance or neutralizing antibodies, and they note that randomized trial evidence is not part of the clinical record described.

For nanotechnology, the authors frame nanoparticles and nanocarriers as platforms intended to improve delivery, penetration, and local activity rather than as a single drug class, and they discuss both antibiotic-coated nanoformulations and metal-based particles with reported multimodal antibacterial effects. Examples include imipenem-loaded zeolite imidazole-8 (ZIF-8) systems and silver- or zinc-based nanoparticles, with reported outcomes spanning enhanced antibacterial activity, antibiofilm effects, and pharmacokinetic changes in animal studies, depending on the formulation described. The review also compiles cross-cutting barriers the authors associate with translation, including toxicity, biodistribution and potential accumulation concerns for nanoparticles, and manufacturing and regulatory complexity for advanced materials and biologics. In discussing oversight, the authors reference FDA guidance on whether a product involves nanotechnology and describe national regulatory efforts such as Brazil’s participation in NANoReg and ANVISA’s RDC No. 751/2022 for device classification and labeling considerations. They also describe the “valley of death” and related funding obstacles as a recurring bottleneck for moving from early research into clinical trials, concluding that the field is rapidly expanding even as standardization, safety, regulatory, and financing constraints are cited as barriers to broader clinical testing.

Key Takeaways:

• The review describes strategy domains beyond conventional antibiotics, including metabolic pathway disruption, nanotechnology/metal nanoparticles, bacteriophages, and drug repurposing.
• Across modalities, the evidence summarized is largely preclinical, with in vivo model findings and a limited set of compassionate-use case reports noted for phage therapy.
• The authors highlight translational barriers that recur across sections, including safety and biodistribution questions for nanoparticles, regulatory/manufacturing complexity, standardization challenges for phage workflows, and funding gaps affecting progression into clinical trials.